IMVT · Immunovant Inc
United States · RS rating 41 · As of 2026-11-03
| Price | 29.04 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 31 / 24 / 66 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 26 / 43 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +16.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +35.4% |
| Market cap (USD) | $5.9B |